Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2015 Jan;13(1):27-36. doi: 10.1016/j.cgh.2014.04.039. Epub 2014 Jun 5.

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.

Author information

1
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
2
Department of Hepatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U773, University of Paris-VII, Clichy, France.
3
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: nafdhal@caregroup.harvard.edu.

Abstract

With widespread screening and increasingly effective treatments for patients with viral hepatitis as well as the increasing prevalence of nonalcoholic fatty liver disease, the population presenting to the care of gastroenterologists and hepatologists is certain to increase. Assessment of advanced liver disease is traditionally invasive and expensive. Vibration-controlled transient elastography, commonly delivered by the FibroScan device, is an option recently approved by the Food and Drug Administration for the noninvasive assessment of liver disease at the point of care. Herein, we review the promise and pitfalls of vibration-controlled transient elastography with the aim of providing clinicians with a framework to interpret its results and apply this technology to the changing needs of our patients.

KEYWORDS:

Cirrhosis; Fibrosis; Hepatitis; Liver Disease; Nonalcoholic Fatty Liver Disease

PMID:
24909907
DOI:
10.1016/j.cgh.2014.04.039
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center